Group 1 - The Shenzhen Stock Exchange announced a periodic adjustment of several indices, including the Shenzhen Component Index and the ChiNext Index, which will take effect on December 15, 2025, with changes to sample stocks [3] - The China Securities Regulatory Commission and stock exchanges are accelerating preparations for commercial real estate REITs, with the expectation that applications will be submitted soon [3] Group 2 - Ruineng Technology reported that approximately 1.02% of its revenue in the first three quarters came from industrial control products applied in the robotics sector [3] - Tailong Pharmaceutical's controlling shareholder is planning a share transfer, which may lead to a change in company control, resulting in a stock suspension starting December 2 [4] - ST Suwu received a decision for the termination of its stock listing [5] - Changhua Group has been designated for a project by a domestic automotive company, with an expected total sales amount of approximately 732 million [5] - Industrial Fulian has repurchased 0.05% of its shares at a cost of 247 million [5] - China Mobile's state-owned share transfer has been approved by the State-owned Assets Supervision and Administration Commission [5] - Hengyi Petrochemical's controlling shareholder plans to increase its stake in the company by 1.5 to 2.5 billion [5] - Yongtai Energy intends to repurchase shares worth 300 to 500 million for capital reduction [5] - Saisir reported November sales of 55,203 new energy vehicles, a year-on-year increase of 49.84% [5] - BYD's November sales of new energy vehicles reached 480,200 units [5] Group 3 - Top Group is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Luxin Investment intends to establish a fund focusing on investments in the life sciences sector [7]

Group 1 - Fuhong Hanlin announced that it will present clinical data for multiple drugs at the ESMO Asia 2025 conference, highlighting the Phase II results of its core asset PD-L1 ADC drug HLX43 in cervical cancer [1] - The development pipeline for PD-L1 ADCs is limited, with Pfizer's PF-08046054 being the fastest, currently in Phase III clinical trials, while HLX43 is leading in development [1] Group 2 - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. has entered a delisting adjustment period after receiving a decision from the Shanghai Stock Exchange to terminate its stock listing, reflecting increased regulatory efforts to clear companies with significant uncertainties in operational sustainability [2] - The delisting of *ST Wuzhong is a typical case of the recent trend in A-shares towards "survival of the fittest," aiming to optimize the market ecosystem and encouraging investors to focus on companies with solid fundamentals and governance [2] Group 3 - Beijing Hotgen Biotech Co., Ltd. and its partners plan to jointly invest in Beijing Yaojing Gene Technology Co., Ltd., with a total investment of 80 million yuan, which will increase Yaojing Gene's registered capital from 110 million yuan to 150 million yuan [3] - Despite the dilution of its stake in Yaojing Gene from 40.91% to 38.00%, Hotgen Biotech maintains its position as a significant shareholder, and the investment is expected to enhance the target company's R&D and operational capabilities [3] Group 4 - The controlling shareholder of Henan Tailong Pharmaceutical Co., Ltd. is planning a major share transfer that may lead to a change in company control, which could optimize the governance structure but also introduce uncertainties in operational strategy [4] - The recent actions in Henan's state-owned enterprise reforms suggest that this share transfer may be part of regional industrial consolidation, prompting investors to pay attention to the strength of the incoming party and potential asset integration [4]

Core Viewpoint - *ST Suwu (600200) is facing delisting as the Shanghai Stock Exchange has decided to terminate its stock listing due to significant violations, including false disclosures in annual reports from 2020 to 2023 [2][4]. Summary by Sections Company Announcement - On December 1, *ST Suwu announced it received a decision from the Shanghai Stock Exchange regarding the termination of its stock listing [2]. Regulatory Actions - On November 25, *ST Suwu received an administrative penalty from the China Securities Regulatory Commission (CSRC) for false disclosures in its annual reports from 2020 to 2023, which constitutes a major violation leading to mandatory delisting [4]. Financial Misconduct - The CSRC identified several violations by *ST Suwu, including: - Failing to disclose the actual controller of the company, with false reporting of the actual controller from 2018 to 2023 [6]. - Inflating revenue and profits through non-commercial trade activities, resulting in inflated revenues of CNY 4.95 billion, 4.69 billion, 4.31 billion, and 3.77 billion for the years 2020 to 2023, respectively, and inflated profits totaling CNY 14.58 million, 20.27 million, 19.92 million, and 21.22 million for the same years [6]. - Not disclosing non-operational fund occupation by related parties, with balances of CNY 1.27 billion, 1.39 billion, 1.54 billion, and 1.69 billion at the end of 2020 to 2023 [7]. Penalties Imposed - The CSRC has mandated *ST Suwu to rectify its violations, issued a warning, and imposed a fine of CNY 10 million. The actual controller, Qian Qunshan, received a warning and a total fine of CNY 15 million, along with a 10-year ban from the securities market [8].

Core Viewpoint - *ST Suwu has received a decision from the Shanghai Stock Exchange to terminate its stock listing due to significant violations, including false disclosures in annual reports and financial misstatements [1][5]. Group 1: Termination of Listing - On December 1, *ST Suwu announced it received a decision from the Shanghai Stock Exchange regarding the termination of its stock listing [1]. - The stock will enter a delisting preparation period starting December 9, with the last trading day expected to be December 29, lasting for 15 trading days [3][6]. - During the delisting preparation period, the stock will trade on a risk warning board [3]. Group 2: Violations and Penalties - The China Securities Regulatory Commission (CSRC) issued an administrative penalty decision on November 25, citing three major violations by *ST Suwu, including failure to disclose the actual controller and false financial reporting from 2018 to 2023 [5]. - The company was fined 10 million yuan, and its chairman and vice chairman were fined a total of 20.5 million yuan for their roles in the violations [5]. - The Shanghai Stock Exchange determined that these violations constituted a mandatory delisting condition under its listing rules [5]. Group 3: Company Profile and Market Data - *ST Suwu is a comprehensive listed company with a core focus on pharmaceuticals, significant involvement in real estate, and investment activities [6]. - As of November 25, the stock was trading at 1.24 yuan per share, with a total market capitalization of 880 million yuan [7]. - As of September 30, the number of shareholders was reported at 67,406, reflecting a decrease of 1,369 shareholders, or a 1.99% change [10][11].

【导读】*ST苏吴收到股票终止上市决定 12月1日晚间，*ST苏吴收到上海证券交易所出具的《关于江苏吴中医药发展股份有限公司股票终止上市的决定》，决定终止公司股票上市。*ST苏吴股票 自12月9日起进入退市整理期。 *ST苏吴被终止上市 12月1日晚间，*ST苏吴发布公告称，公司收到上海证券交易所出具的《关于江苏吴中医药发展股份有限公司股票终止上市的决定》，决定终止公司股票 上市。 根据公告，*ST苏吴股票进入退市整理期的起始日为12月9日，预计最后交易日期为12月29日，退市整理期的交易期限为15个交易日。退市整理期间股票 在风险警示板交易。公司股票终止上市后，将转入全国中小企业股份转让系统进行股份转让。 年报存在虚假记载 11月25日，*ST苏吴收到中国证监会出具的《行政处罚决定书》（〔2025〕145号）。经查，*ST苏吴及相关当事人存在以下三项违法事实： 一是未如实披露实际控制人，2018年至2023年年报存在虚假记载；二是虚增营业收入、营业成本和利润，2020年至2023年年报存在虚假记载；三是未按规 定披露关联方非经营性占用资金情况，2020年至2023年年报存在重大遗漏。 根据当事人违法行为的事 ...

12月1日晚间，*ST苏吴发布公告称，公司收到上海证券交易所出具的《关于江苏吴中医药发 展股份有限公司股票终止上市的决定》，决定终止公司股票上市。 【导读】*ST苏吴收到股票终止上市决定 中国基金报记者 李智 12月1日晚间，*ST苏吴收到上海证券交易所出具的《关于江苏吴中医药发展股份有限公司股 票终止上市的决定》，决定终止公司股票上市。*ST苏吴股票自12月9日起进入退市整理期。 *ST苏吴被终止上市 根据公告，*ST苏吴股票进入退市整理期的起始日为12月9日，预计最后交易日期为12月29 日，退市整理期的交易期限为15个交易日。退市整理期间股票在风险警示板交易。公司股票 终止上市后，将转入全国中小企业股份转让系统进行股份转让。 停牌前，*ST苏吴曾实现5连板。截至11月25日收盘，该股报1.24元/股，总市值为8.8亿 元。 截至9月30日，*ST苏吴的股东户数为6.74万户。 | 截止日期 - | 股东总户数(户) | | | --- | --- | --- | | 本期数 变动数 变动率(%) | | | | 2025-09-30 67,406 -1,369 | | -1.99 | | 2025-06 ...

Core Viewpoint - *ST Suwu has received a decision from the Shanghai Stock Exchange to terminate its stock listing due to significant violations, including false disclosures in annual reports from 2020 to 2023 [2][4]. Group 1: Termination of Listing - The termination of *ST Suwu's stock listing will take effect after a 15-day trading period, starting from December 9, 2025, with the last trading day expected to be December 29, 2025 [2][4]. - The stock will enter a delisting preparation period, where the first trading day will have no price limits, while subsequent days will have a 10% price limit [4]. Group 2: Violations and Penalties - The company has been found to have inflated revenue, costs, and profits through non-commercial transactions with related parties, resulting in inflated revenues of CNY 4.95 billion, CNY 4.69 billion, CNY 4.31 billion, and CNY 3.77 billion from 2020 to 2023 [5]. - The China Securities Regulatory Commission (CSRC) has imposed a fine of CNY 10 million on *ST Suwu and warned the company to rectify its violations, while also fining five responsible individuals a total of CNY 20.5 million [6]. Group 3: Business Overview - *ST Suwu operates primarily in two sectors: the pharmaceutical industry and the medical beauty biotechnology sector, with a focus on chemical generic drugs and regenerative medical injectables [4].

这家上市公司，退市倒计时。停牌前*ST苏吴走出5连板。 12月1日晚间，*ST苏吴(600200)披露公告称，公司于12月1日收到上海证券交易所出具的《关于江苏吴中医药发展股份有限公司 股票终止上市的决定》，上海证券交易所决定终止公司股票上市。 | 显示停牌 到价提醒 | 筹码 | 0 1 KS | *ST苏吴 | | | | | --- | --- | --- | --- | --- | --- | --- | | 设置均线。 | | | 600200 | | | | | 025/9/11-2025/11/25(48根) | | | 停牌 CNY | | ● 自选 | | | œ | * 1 1 | | 型化 | - 委主 | | | | | | 1.24 | 菜工 | | 0 | | | 1.24 | | | 卖四 | | 0 | | | | | 1.18 | ik h | | 0 | | | | | | | | O | | | | | 1.12 | | | 0 | | | | | | 彩票 | | 0 | | | | | 1.06 | | | 0 | | | | | | 云三 | | 0 | | | | ...

*ST苏吴(600200)将进入退市整理期。 12月1日晚间，*ST苏吴(600200)发布公告称，公司当日收到上交所出具的《关于江苏吴中医药发展股份 有限公司股票终止上市的决定》，上交所决定终止公司股票上市。 公司股票将于2025年12月9日进入退市整理期，股票简称变更为"退市苏吴"，预计最后交易日期为2025年 12月29日。退市整理期间，公司股票将在上交所风险警示板交易，首个交易日无价格涨跌幅限制，此后 每日涨跌幅限制为10%。退市整理期届满后5个交易日内，上交所将对公司股票予以摘牌，公司股票终止 上市。 此前，公司在11月25日收到证监会下发的《行政处罚决定书》，认定：1.公司未如实披露实际控制人， 2018年至2023年年度报告存在虚假记载；2.虚增营业收入、营业成本和利润，未按规定披露关联方非经营 性占用资金情况，2020年至2023年年度报告存在虚假记载和重大遗漏。同日，公司还收到上交所下发的 《关于拟终止江苏吴中医药发展股份有限公司股票上市的事先告知书》。 由于触及《上海证券交易所股票上市规则》规定的重大违法强制退市情形，公司股票将被实施重大违法 强制退市，自2025年11月26日起停牌。 《 ...

*ST苏吴（600200）将进入退市整理期。 12月1日晚间， *ST苏吴（600200）发布公告称，公司当日收到上交所出具的《关于江苏吴中医药发展股份有限 公司股票终止上市的决定》，上交所决定终止公司股票上市。 此前，公司在11月25日收到证监会下发的《行政处罚决定书》，认定：1.公司未如实披露实际控制人，2018年至 2023年年度报告存在虚假记载；2.虚增营业收入、营业成本和利润，未按规定披露关联方非经营性占用资金情 况，2020年至2023年年度报告存在虚假记载和重大遗漏。 同日，公司还收到上交所下发的《关于拟终止江苏吴 中医药发展股份有限公司股票上市的事先告知书》。 由于触及《上海证券交易所股票上市规则》规定的重大违法强制退市情形，公司股票将被实施重大违法强制退 市，自2025年11月26日起停牌。 《行政处罚决定书》显示，2018年2月，*ST苏吴控股股东苏州吴中投资控股有限公司发生股权变更，变更 后，钱群山实际支配*ST苏吴行为，成为*ST苏吴实际控制人。*ST苏吴2018年至2023年年度报告披露钱群英 为实际控制人，存在虚假记载。 同时，*ST苏吴子公司江苏吴中进出口有限公司、中吴贸易发展( ...